Loading…
Hosted by Scientific Education Support · 🇺🇸 US · EN · 43 episodes
Established thought leaders with verified media credentials.
The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.
Scientific Education Support hosts AML Hub, a education show with 43 episodes published.
The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insights have been gaine
The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What might the future hold for the evolution of FLT3 inhibitors in the treatment of AML? Stein summarizes
The AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What are the key ongoing questions in FLT3-mutated AML, and how are ongoing trials addressing these?
During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Cortes chaired a discussion on the topic, Menin inhibitors in AML: Where are we now, and where are we going? The discussion featured co
The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach managing them in cli
The AML Hub was pleased to speak with Eunice Wang from Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the mechanisms and rationale for menin inhibitor combination strategies? Wang summarizes th
During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Sierra chaired a discussion on the topic, Treatment decisions in acute myeloid leukemia (AML): Personalizing care with FLT3 inhibitor t
The AML Hub was pleased to speak with Joshua Zeidner, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What key insights are emerging from ongoing trials of menin inhibitor
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3 -ITD and -TKD mutations in AML: Implications for clinical practice. The symposiu
The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3 -ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the symp
The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the webinar by Jor
The AML Hub held a webinar on November 19, 2025, titled, “Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice.” Here, we share one of the presentations, by Jorge S
Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, Wh
Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We ask
The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the latest data presented on current and emerging treatments for acute myeloid leukemia (AML)? S
The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial data and clinical prac
During a meeting of the AML Hub Steering Committee, held on July 22, 2025, Charles Craddock chaired a discussion on the topic: Addressing uncertainty in patient selection for transplant. The discussion featured contribut
The AML Hub was pleased to speak with Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina Lineberger Comprehensive Cancer Center in Durham, North Carolina. We asked for his thoughts on the
Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the audience
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hosted a webinar for 
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
AML Hub has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their education audience.
AML Hub is hosted by Scientific Education Support. The show is categorised under education and has published 43 episodes.
AML Hub has published 43 episodes.
AML Hub regularly covers education. It sits in the education category.
AML Hub is accessible for guests with genuine education expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
AML Hub hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of AML Hub average 11 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates AML Hub's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.